Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.

FOS PVRL4 breast cancer nectin‑4

Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 27 04 2023
accepted: 04 10 2023
medline: 8 12 2023
pubmed: 8 12 2023
entrez: 8 12 2023
Statut: ppublish

Résumé

PVRL4 (or nectin‑4) is a promising therapeutic target since its upregulated expression is found in a wide range of human cancer types. Enfortumab vedotin, an antibody‑drug conjugate targeting PVRL4, is clinically used for the treatment of urothelial bladder cancer. In addition, rMV‑SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through interaction with PVRL4. Although

Identifiants

DOI: 10.3892/or.2023.8676 PMID: 38063270
pubmed: 38063270
doi: 10.3892/or.2023.8676
pii: 17
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Tomoyuki Nanamiya (T)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Kiyoko Takane (K)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Kiyoshi Yamaguchi (K)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Yuya Okawara (Y)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Mariko Arakawa (M)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Akari Saku (A)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Tsuneo Ikenoue (T)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Tomoko Fujiyuki (T)

Division of Virus Engineering, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.

Misako Yoneda (M)

Division of Virological Medicine, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.

Chieko Kai (C)

Division of Infectious Disease Control Science, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.

Yoichi Furukawa (Y)

Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.

Classifications MeSH